WO2023103335A1 - 双特异性抗体及其应用 - Google Patents
双特异性抗体及其应用 Download PDFInfo
- Publication number
- WO2023103335A1 WO2023103335A1 PCT/CN2022/100475 CN2022100475W WO2023103335A1 WO 2023103335 A1 WO2023103335 A1 WO 2023103335A1 CN 2022100475 W CN2022100475 W CN 2022100475W WO 2023103335 A1 WO2023103335 A1 WO 2023103335A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- variable region
- amino acid
- acid sequence
- antibody
- Prior art date
Links
- 101100460850 Homo sapiens NCR3LG1 gene Proteins 0.000 claims abstract description 163
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims abstract description 163
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 128
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims abstract description 115
- 210000004027 cell Anatomy 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 57
- 150000007523 nucleic acids Chemical class 0.000 claims description 40
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 239000013604 expression vector Substances 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 19
- 108010075254 C-Peptide Proteins 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 201000007270 liver cancer Diseases 0.000 claims description 13
- 208000014018 liver neoplasm Diseases 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 13
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 12
- 206010038038 rectal cancer Diseases 0.000 claims description 12
- 201000001275 rectum cancer Diseases 0.000 claims description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 210000004899 c-terminal region Anatomy 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 241001529936 Murinae Species 0.000 claims description 2
- 241000288906 Primates Species 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000005760 tumorsuppression Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 59
- 210000004881 tumor cell Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 26
- 230000027455 binding Effects 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 239000000872 buffer Substances 0.000 description 18
- 238000001727 in vivo Methods 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000006044 T cell activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 230000003836 peripheral circulation Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000006052 T cell proliferation Effects 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 description 1
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 1
- 101000633520 Homo sapiens Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 description 1
- 101000699762 Homo sapiens RNA 3'-terminal phosphate cyclase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100029143 RNA 3'-terminal phosphate cyclase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 102000048679 human NCR3LG1 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- -1 recombinant cell Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Abstract
Description
Claims (26)
- 一种重组抗体,其特征在于,含有选自下列至少之一的CDR序列或与其具有至少95%同一性的氨基酸序列:CD3抗体可变区CDR序列:SEQ ID NO:1~6;B7H6抗体可变区CDR序列:SEQ ID NO:7~12。
- 根据权利要求1所述的重组抗体,其特征在于,含有CD3抗体的可变区,所述CD3抗体的可变区具有如SEQ ID NO:13所示的轻链可变区,和SEQ ID NO:14所示的重链可变区,或者与SEQ ID NO:13和SEQ ID NO:14所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列。
- 根据权利要求1所述的重组抗体,其特征在于,所述抗体含有B7H6抗体的可变区,所述B7H6抗体的可变区具有如SEQ ID NO:20所示的轻链可变区,和SEQ ID NO:23所示氨基酸序列的重链可变区,或者与SEQ ID NO:20和SEQ ID NO:23所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:16所示的轻链可变区,和SEQ ID NO:22所示氨基酸序列的重链可变区,或者与SEQ ID NO:16和SEQ ID NO:22所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:16所示的轻链可变区,和SEQ ID NO:23所示氨基酸序列的重链可变区,或者与SEQ ID NO:16和SEQ ID NO:23所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:16所示的轻链可变区,和SEQ ID NO:24所示氨基酸序列的重链可变区,或者与SEQ ID NO:16和SEQ ID NO:24所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:16所示的轻链可变区,和SEQ ID NO:25所示氨基酸序列的重链可变区,或者与SEQ ID NO:16和SEQ ID NO:25所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:17所示的轻链可变区,和SEQ ID NO:22所示氨基酸序列的重链可变区,或者与SEQ ID NO:17和SEQ ID NO:22所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:17所示的轻链可变区,和SEQ ID NO:23所示氨基酸序列的重链可变区,或者与SEQ ID NO:17和SEQ ID NO:23所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:17所示的轻链可变区,和SEQ ID NO:24所示氨基酸序列的重链可变区,或者与SEQ ID NO:17和SEQ ID NO:24所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:17所示的轻链可变区,和SEQ ID NO:25所示氨基酸序列的重链可变区,或者与SEQ ID NO:17和SEQ ID NO:25所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:19所示的轻链可变区,和SEQ ID NO:22所示氨基酸序列的重链可变区,或者与SEQ ID NO:19和SEQ ID NO:22所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:19所示的轻链可变区,和SEQ ID NO:23所示氨基酸序列的重链可变区,或者与SEQ ID NO:19和SEQ ID NO:23所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:19所示的轻链可变区,和SEQ ID NO:24所示氨基酸序列的重链可变区,或者与SEQ ID NO:19和SEQ ID NO:24所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:19所示的轻链可变区,和SEQ ID NO:25所示氨基酸序列的重链可变区, 或者与SEQ ID NO:19和SEQ ID NO:25所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:20所示的轻链可变区,和SEQ ID NO:22所示氨基酸序列的重链可变区,或者与SEQ ID NO:20和SEQ ID NO:22所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:20所示的轻链可变区,和SEQ ID NO:24所示氨基酸序列的重链可变区,或者与SEQ ID NO:20和SEQ ID NO:24所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:20所示的轻链可变区,和SEQ ID NO:25所示氨基酸序列的重链可变区,或者与SEQ ID NO:20和SEQ ID NO:25所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:15所示的轻链可变区,和SEQ ID NO:26所示氨基酸序列的重链可变区,或者与SEQ ID NO:15和SEQ ID NO:26所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列;所述B7H6抗体的可变区具有如SEQ ID NO:18所示的轻链可变区,和SEQ ID NO:21所示氨基酸序列的重链可变区,或者与SEQ ID NO:18和SEQ ID NO:21所示的氨基酸序列具有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少99%同一性的氨基酸序列。
- 根据权利要求1所述的重组抗体,其特征在于,进一步包括连接肽;任选地,所述连接肽具有SEQ ID NO:46所示的氨基酸序列。
- 根据权利要求4所述的重组抗体,所述连接肽的N端与所述CD3抗体轻链可变区的C端相连,所述连接肽的C端与所述CD3抗体重链可变区的N端相连。
- 根据权利要求4所述的重组抗体,所述所述连接肽的N端与所述B7H6轻链可变区的C端相连,所述连接肽的C端与所述B7H6重链可变区的N端相连。
- 根据权利要求1所述的重组抗体,其特征在于,还含有第一Fc区和第二Fc区,所述第一Fc区和第二Fc区的至少一部分来自于鼠源抗体、人源抗体、灵长目源抗体或其突变体的至少之一。
- 根据权利要求7所述的重组抗体,其特征在于,所述第一Fc区和第二Fc区的至少一部分来自人源IgG或其突变体;任选地,所述第一Fc区和第二Fc区的至少一部分来自人源IgG1或其突变体。
- 根据权利要求7所述的重组抗体,其特征在于,所述第一Fc区与野生型IgG1 Fc区相比具有S384C突变和T396W突变中的至少之一。
- 根据权利要求9所述的重组抗体,其特征在于,所述第二Fc区与野生型IgG1 Fc区相比具有Y380C突变、T397S突变、L399A突变和Y408V突变中的至少之一。
- 根据权利要求7-10任一项所述的重组抗体,其特征在于,所述第一抗体Fc区具有如SEQ ID NO:47所示的氨基酸序列,所述第二抗体Fc区具有如SEQ ID NO:48所示的氨基酸序列。
- 一种重组抗体,其特征在于,具有SEQ ID NO:49和63所示的氨基酸序列。
- 一种核酸,其特征在于,所述核酸编码权利要求1-12任一项所述的重组抗体。
- 根据权利要求13所述的核酸,其特征在于,具有SEQ ID NO:69所示的核苷酸序列,以及SEQ ID NO:70-87所示的核苷酸序列中的至少之一。
- 一种表达载体,其特征在于,所述表达载体携带权利要求13或14所述的核酸分子。
- 一种重组细胞,其特征在于,所述重组细胞携带权利要求13或14所述的核酸分子、权利要求15所述的表达载体或权利要求1-12任一项所述的重组抗体。
- 一种组合物,其特征在于,包括:权利要求1-12任一项所述的重组抗体、权利要求13或14所述的核酸分子、权利要求15所述的表达载体或权利要求16所述的重组细胞。
- 权利要求1-12任一项所述的重组抗体、权利要求13或14所述的核酸分子、权利要求15所述的表达载体、权利要求16所述的重组细胞或权利要求17所述的组合物在制备药物中的用途,所述药物用于治疗或预防癌症。
- 根据权利要求18所述的用途,其特征在于,所述癌症包括下列中的至少之一:直肠癌、非小细胞肺癌、乳腺癌 和肝癌。
- 一种药物,其特征在于,包括:权利要求1-12任一项所述的重组抗体、权利要求13或14所述的核酸分子、权利要求15所述的表达载体、权利要求16所述的重组细胞或权利要求17所述的组合物,所述药物用于治疗或预防癌症。
- 根据权利要求20所述的药物,其特征在于,所述癌症包括下列中的至少之一:直肠癌、非小细胞肺癌、乳腺癌和肝癌。
- 一种试剂盒,其特征在于,包括:权利要求1-12任一项所述的重组抗体。根据权利要求20所述的试剂盒,其特征在于,所述试剂盒用于诊断直肠癌、非小细胞肺癌、乳腺癌和肝癌中的至少之一。
- 权利要求1-12任一项所述的重组抗体、权利要求13或14所述的核酸分子、权利要求15所述的表达载体、权利要求16所述的重组细胞、权利要求17所述的组合物或权利要求21-22任一项所述的药物在治疗或预防癌症中的用途。
- 根据权利要求24所述的用途,其特征在于,所述癌症包括下列中的至少之一:直肠癌、非小细胞肺癌、乳腺癌和肝癌。
- 一种治疗或预防癌症的方法,其特征在于,包括向受试者施用以下中的至少之一:1)权利要求1-12任一项所述的重组抗体;2)权利要求13或14所述的核酸分子;3)权利要求15所述的表达载体;4)权利要求16所述的重组细胞;5)权利要求17所述的组合物;或6)权利要求21-22任一项所述的药物。
- 根据权利要求26所述的方法,其特征在于,所述癌症包括下列中的至少之一:直肠癌、非小细胞肺癌、乳腺癌和肝癌。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22902772.7A EP4321536A1 (en) | 2021-12-07 | 2022-06-22 | Bispecific antibody and use thereof |
CA3211762A CA3211762A1 (en) | 2021-12-07 | 2022-06-22 | Bispecific antibodies and uses of the same thereof |
KR1020237042882A KR20240007927A (ko) | 2021-12-07 | 2022-06-22 | 이중 특이성 항체 및 이의 응용 |
IL308361A IL308361A (en) | 2021-12-07 | 2022-06-22 | Antibodies with dual specificity and their uses |
AU2022404170A AU2022404170A1 (en) | 2021-12-07 | 2022-06-22 | Bispecific antibody and use thereof |
ZA2023/11420A ZA202311420B (en) | 2021-12-07 | 2023-12-12 | Bispecific antibodies and uses of the same thereof |
US18/389,819 US20240124615A1 (en) | 2021-12-07 | 2023-12-20 | Bispecific antibodies and uses of the same thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111485404.0A CN114395047B (zh) | 2021-12-07 | 2021-12-07 | 双特异性抗体及其应用 |
CN202111485404.0 | 2021-12-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US18/389,819 Continuation US20240124615A1 (en) | 2021-12-07 | 2023-12-20 | Bispecific antibodies and uses of the same thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023103335A1 true WO2023103335A1 (zh) | 2023-06-15 |
Family
ID=81225458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/100475 WO2023103335A1 (zh) | 2021-12-07 | 2022-06-22 | 双特异性抗体及其应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20240124615A1 (zh) |
EP (1) | EP4321536A1 (zh) |
KR (1) | KR20240007927A (zh) |
CN (1) | CN114395047B (zh) |
AU (1) | AU2022404170A1 (zh) |
CA (1) | CA3211762A1 (zh) |
IL (1) | IL308361A (zh) |
TW (1) | TW202313700A (zh) |
WO (1) | WO2023103335A1 (zh) |
ZA (1) | ZA202311420B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
CN115611985A (zh) * | 2022-10-27 | 2023-01-17 | 合肥天港免疫药物有限公司 | 抗cd3的抗体及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511278A (zh) * | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
WO2021064137A2 (en) * | 2019-10-02 | 2021-04-08 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins for cancer treatment |
CN113286821A (zh) * | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | 靶向肿瘤的激动性cd28抗原结合分子 |
CN114395044A (zh) * | 2021-12-07 | 2022-04-26 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
CN114395047A (zh) * | 2021-12-07 | 2022-04-26 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2783740C (en) * | 2009-12-09 | 2020-03-10 | Institut National De La Sante Et De La Recherche Medicale | Monoclonal antibodies that bind b7h6 and uses thereof |
AR087601A1 (es) * | 2011-08-23 | 2014-04-03 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion |
KR20240017102A (ko) * | 2013-12-17 | 2024-02-06 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법 |
MX2017015011A (es) * | 2015-05-28 | 2018-03-23 | Genentech Inc | Ensayo a base de celulas para detectar homodimeros anti-cd3. |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
US11034767B2 (en) * | 2016-04-15 | 2021-06-15 | Trustees Of Dartmouth College | High affinity B7-H6 antibodies and antibody fragments |
TWI805665B (zh) * | 2017-12-21 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | 結合hla-a2/wt1之抗體 |
-
2021
- 2021-12-07 CN CN202111485404.0A patent/CN114395047B/zh active Active
-
2022
- 2022-06-22 CA CA3211762A patent/CA3211762A1/en active Pending
- 2022-06-22 EP EP22902772.7A patent/EP4321536A1/en active Pending
- 2022-06-22 IL IL308361A patent/IL308361A/en unknown
- 2022-06-22 KR KR1020237042882A patent/KR20240007927A/ko unknown
- 2022-06-22 WO PCT/CN2022/100475 patent/WO2023103335A1/zh active Application Filing
- 2022-06-22 AU AU2022404170A patent/AU2022404170A1/en active Pending
- 2022-12-07 TW TW111146967A patent/TW202313700A/zh unknown
-
2023
- 2023-12-12 ZA ZA2023/11420A patent/ZA202311420B/en unknown
- 2023-12-20 US US18/389,819 patent/US20240124615A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110511278A (zh) * | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
CN113286821A (zh) * | 2018-12-21 | 2021-08-20 | 豪夫迈·罗氏有限公司 | 靶向肿瘤的激动性cd28抗原结合分子 |
WO2021064137A2 (en) * | 2019-10-02 | 2021-04-08 | Boehringer Ingelheim International Gmbh | Multi-specific binding proteins for cancer treatment |
CN114395044A (zh) * | 2021-12-07 | 2022-04-26 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
CN114395047A (zh) * | 2021-12-07 | 2022-04-26 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
Non-Patent Citations (1)
Title |
---|
SUN XIN; ZHAO JINGYUAN; MA LI; SUN XIMING; GE JING; YU YANG; MA JUAN; ZHANG MAN: "B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells", INVESTIGATIONAL NEW DRUGS, SPRINGER US, NEW YORK, vol. 39, no. 1, 7 August 2021 (2021-08-07), New York, pages 24 - 33, XP037353706, ISSN: 0167-6997, DOI: 10.1007/s10637-020-00976-5 * |
Also Published As
Publication number | Publication date |
---|---|
CN114395047B (zh) | 2023-11-07 |
TW202313700A (zh) | 2023-04-01 |
IL308361A (en) | 2024-01-01 |
US20240124615A1 (en) | 2024-04-18 |
CA3211762A1 (en) | 2023-06-15 |
EP4321536A1 (en) | 2024-02-14 |
KR20240007927A (ko) | 2024-01-17 |
AU2022404170A1 (en) | 2023-09-21 |
CN114395047A (zh) | 2022-04-26 |
ZA202311420B (en) | 2024-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6906653B2 (ja) | 三重特異性結合タンパク質と使用方法 | |
KR102037016B1 (ko) | 항 pd-l1 나노 항체 및 이의 응용 | |
WO2023103335A1 (zh) | 双特异性抗体及其应用 | |
WO2018071777A1 (en) | Innate immune cell trispecific binding proteins and methods of use | |
US20220002408A1 (en) | Bispecific antibody, preparation method thereof and application thereof | |
CN114395044B (zh) | 重组抗体及其应用 | |
CN113543804A (zh) | 抗lilrb2抗体及其使用方法 | |
CN111269315B (zh) | 针对bcma的单克隆抗体 | |
JP2021526012A (ja) | Ctla−4を標的とする抗体、その調製方法および使用 | |
CN110366563A (zh) | 抗lilrb3抗体及其使用方法 | |
JP7461397B2 (ja) | 免疫調節及び抗腫瘍関連ナノボディ及びその核酸コード配列、並びにその使用 | |
WO2019192493A1 (zh) | 抗人lag-3单克隆抗体及其应用 | |
WO2023001154A1 (zh) | 一种b7-h3抗体及其应用 | |
CN115232213A (zh) | 双特异性抗体及其应用 | |
EP4130039A1 (en) | Development and application of immune cell activator | |
CN116323655A (zh) | 一种SIRPα-Fc融合蛋白 | |
CN114409797A (zh) | 重组抗体及其应用 | |
WO2022262783A1 (zh) | 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用 | |
TWI816621B (zh) | 抗體及其應用 | |
JP7346576B2 (ja) | 抗ox40モノクローナル抗体とその応用 | |
CN111484554B (zh) | 一种靶向4-1bb的肿瘤抑制性抗体及其应用 | |
US20220106402A1 (en) | Antibody | |
RU2776638C1 (ru) | Антитела против vsig4 человека и их применение | |
WO2023208191A1 (zh) | 一种重组抗体及其应用 | |
WO2024005204A1 (ja) | 融合タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22902772 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022404170 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3211762 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022404170 Country of ref document: AU Date of ref document: 20220622 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022902772 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 308361 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023128925 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2022902772 Country of ref document: EP Effective date: 20231106 |
|
ENP | Entry into the national phase |
Ref document number: 20237042882 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020237042882 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/015244 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023026353 Country of ref document: BR |